Glucagon-like peptide-1 receptor agonists are the most commercially significant peptide class developed to date, and their success reshaped what the field considers achievable for peptide medicines.
Key Takeaways
- GLP-1 is an incretin hormone released from intestinal L-cells that potentiates glucose-dependent insulin secretion.
- An oral semaglutide product was developed using an absorption enhancer, which was a notable technical milestone given how poorly peptides cross the intestinal epithelium.
- The class demonstrated that peptides can be chronic, self-administered, commercially dominant medicines.
The native hormone and its problem
GLP-1 is an incretin hormone released from intestinal L-cells that potentiates glucose-dependent insulin secretion. The native peptide is degraded within minutes by dipeptidyl peptidase-4, which made the unmodified hormone useless as a medicine and set the engineering problem.
Engineering around rapid clearance
Two strategies dominate: DPP-4-resistant analogues with amino acid substitution at the cleavage site, and conjugation to albumin-binding lipid chains or larger carriers that reduce renal filtration. Both approaches extend exposure without losing receptor activation.
For related mechanism work, see peptide immunogenicity.
Oral formulation achievements
An oral semaglutide product was developed using an absorption enhancer, which was a notable technical milestone given how poorly peptides cross the intestinal epithelium. Bioavailability remains low, but the product demonstrated that the barrier is not absolute.
Dual and triple agonists
Compounds acting on GLP-1 together with GIP or glucagon receptors have reached the market or late-stage development, with tirzepatide the most prominent example. Multi-agonist design is now a central theme rather than an exception.
What this means for the wider field
The class demonstrated that peptides can be chronic, self-administered, commercially dominant medicines. That has redirected investment across the whole category, including into areas where peptide development was previously considered impractical.
Experimental Conditions and Practical Setup
Receptor activation is measured in cell lines expressing the receptor, with cyclic AMP accumulation or a reporter readout as the endpoint, and albumin binding assessed separately by ultrafiltration or surface plasmon resonance. Distinguishing receptor potency from exposure is essential, because much of the clinical difference between agents comes from pharmacokinetics rather than affinity.
Two engineering strategies in the class
| Strategy | Mechanism | Result |
|---|---|---|
| DPP-4-resistant substitution | Blocks the cleavage site | Longer residence at the receptor |
| Albumin-binding lipid chain | Reduces renal filtration | Extended circulating half-life |
| Oral absorption enhancer | Transiently opens epithelium | Oral route with low bioavailability |
| Multi-agonist design | Engages additional receptors | Different efficacy and tolerability profile |
Practical Notes for the Bench
- Distinguish DPP-4 resistance from albumin-binding half-life extension.
- Treat oral bioavailability as the exception rather than the norm.
- Note that multi-agonist design is now mainstream in metabolic peptides.
Frequently Asked Questions
Why did native GLP-1 fail as a drug?
Because dipeptidyl peptidase-4 cleaves it within minutes, giving far too short a duration of action.
How is half-life extended?
Either by substituting the cleavage site to resist DPP-4, or by adding an albumin-binding moiety that reduces renal clearance.
Are oral peptides now routine?
No. Oral semaglutide is a notable exception achieved with an absorption enhancer, and bioavailability remains low.
Is oral delivery now standard for this class?
No. An oral product exists for one agent using an absorption enhancer, but bioavailability remains low and the route is the exception rather than the rule.
Related Reading
- peptide immunogenicity
- peptide stapling technology
- generic peptide development
- milk-derived bioactive peptides
- carnosine dipeptide research
References & Further Reading
- Moiz A et al. Mechanisms of GLP-1 Receptor Agonist-Induced Weight Loss: A Review of Central and Peripheral Pathways in Appetite and Energy Regulation. Am J Med. 2025. PubMed 39892489
- Urbina J et al. Micronutrient and Nutritional Deficiencies Associated With GLP-1 Receptor Agonist Therapy: A Narrative Review. Clin Obes. 2026. PubMed 41549912
- Mullur N et al. GLP-1 receptor agonist-based therapies and cardiovascular risk: a review of mechanisms. J Endocrinol. 2024. PubMed 39145614
- Peptide literature search on PubMed
- Full-text archive at PubMed Central
- FDA guidance documents on peptide drug products
Educational content for research staff. Nothing here should be read as advice on human or veterinary use of any compound.
Reviewed by Dr. Marcus Feld, Molecular Pharmacology, In Vitro Models.